Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low – Time to Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $7.39 and last traded at $7.4390, with a volume of 31094 shares changing hands. The stock had previously closed at $7.58.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Negative Sentiment: Hagens Berman issues reminder to Telix investors about the Jan. 9 lead‑plaintiff deadline, alleging misstatements on TLX591 progress and manufacturing reliability. Telix Pharmaceuticals (TLX) Faces Securities Class Action…
• Negative Sentiment: Levi & Korsinsky notifies investors of a securities‑law suit against Telix and solicits potential lead plaintiffs ahead of the Jan. 9 deadline. Telix Pharmaceuticals Ltd. Sued for Securities Law Violations…
• Negative Sentiment: Berger Montague alerts shareholders about a filed class action covering purchases from Feb. 21, 2025–Aug. 28, 2025 and the Jan. 9 lead‑plaintiff deadline. TELIX PHARMACEUTICALS (NASDAQ: TLX) CLASS ACTION DEADLINE APPROACHING…
• Negative Sentiment: Faruqi & Faruqi announces an investigation and reminds investors of the Jan. 9 deadline for lead‑plaintiff motions in the Telix securities case. Faruqi & Faruqi LLP: SHAREHOLDER ACTION REMINDER…
• Negative Sentiment: Bragar Eagel & Squire issues an urgent deadline alert for Telix stockholders detailing alleged losses during the Feb.–Aug. 2025 class period. TELIX URGENT CLASS ACTION DEADLINE ALERT…
• Negative Sentiment: The Gross Law Firm notifies Telix shareholders to contact the firm before Jan. 9 about potential claims related to the same class period and alleged misstatements. Investors in Telix Pharmaceuticals Ltd. Should Contact The Gross Law Firm…

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TLX shares. Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. UBS Group dropped their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Royal Bank Of Canada started coverage on Telix Pharmaceuticals in a research report on Monday, December 15th. They set a “hold” rating for the company. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Trading Down 2.6%

The business’s 50-day moving average is $9.17 and its 200-day moving average is $11.13.

Institutional Trading of Telix Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Millennium Management LLC purchased a new position in Telix Pharmaceuticals during the third quarter valued at approximately $1,883,000. Pier Capital LLC purchased a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at approximately $3,037,000. Portland Investment Counsel Inc. acquired a new position in shares of Telix Pharmaceuticals in the 3rd quarter valued at $1,225,000. Lazard Asset Management LLC acquired a new position in shares of Telix Pharmaceuticals in the 3rd quarter valued at $1,097,000. Finally, Russell Investments Group Ltd. purchased a new stake in Telix Pharmaceuticals during the second quarter worth $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.